Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on endovascular robotics through its LIBERTY Endovascular Robotic System. The news around MBOT centers on the commercialization of this FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures and the company’s progress in bringing it into routine clinical use.
Investors and clinicians following Microbot Medical can find updates on key commercial milestones, such as the limited market release of LIBERTY in selected high procedure volume regions in the U.S. and the company’s plans for a broader market release aligned with major medical conferences. News items also cover the first hospital adoption of LIBERTY for patient care at Emory University Hospital and the collaboration to build an Endovascular Robotics Program in interventional radiology.
Coverage of MBOT includes regulatory and clinical developments, including FDA 510(k) clearance for LIBERTY and reported data from the ACCESS PVI pivotal trial, where the company cites 100% robotic navigation success, a 92% reduction in radiation exposure and no adverse device events. Additional articles highlight Microbot Medical’s presence at professional meetings, its partnerships with third-party manufacturers and logistics providers, and its work on teleintervention and autonomous robotics collaborations.
Financial and corporate news for Microbot Medical features capital-raising activities through exercises of preferred investment options, as well as updates on its intellectual property portfolio, such as new patents in jurisdictions including Japan. For readers tracking MBOT, this news feed offers a focused view of how the company is advancing the LIBERTY System, expanding its commercial infrastructure and executing on its endovascular robotics strategy over time.
Microbot Medical (Nasdaq: MBOT) has announced a $13 million registered direct offering priced at-the-market, selling 6,103,289 shares of common stock at $2.13 per share. The company is also conducting a concurrent private placement of unregistered short-term series I preferred investment options.
These investment options allow the purchase of up to 12,206,578 additional shares at $2.13 per share, exercisable for two years following stockholder approval. The closing is expected around February 11, 2025, with H.C. Wainwright & Co. serving as the exclusive placement agent.
The net proceeds will fund the development and commercialization of the LIBERTY® Robotic System, expand applications from existing IP portfolio, and provide working capital. The offering is made under a previously filed S-3 registration statement, while the preferred investment options are issued under Section 4(a)(2) of the Securities Act.
Microbot Medical (Nasdaq: MBOT) announced the acceptance of a late-breaking abstract for presentation at the Society of Interventional Radiology (SIR) annual meeting in Nashville from March 29 - April 2, 2025. The presentation will feature first-time data from the ACCESS-PVI trial, a prospective, multicenter, single-arm study evaluating the performance and safety of the LIBERTY® Endovascular Robotic System in peripheral vascular interventions.
The presentation titled 'Remote-controlled endovascular navigation with a miniature, single-use, robotic system. Results of the ACCESS-PVI trial' will be delivered by Dr. Francois Cornelis from Memorial Sloan Kettering Cancer Center on April 2, 2025. The company views this acceptance as significant since the conference attendees represent potential LIBERTY® system users.
Microbot Medical (Nasdaq: MBOT) has appointed Michal Ahuvia as Director of Operations to support the anticipated commercial launch of its LIBERTY® Endovascular Robotic System in Q2 2025. Ahuvia, who brings over 20 years of operations experience, will focus on ramping up production and improving efficiencies in preparation for commercialization.
Reporting to Simon Sharon, the Company's General Manager and Chief Technology Officer, Ahuvia will be responsible for strengthening manufacturing and operations processes. Her extensive background includes roles at Philips Healthcare, Nanomotion, XACT Robotics, and Jordan Valley, with expertise in process transformation, performance improvement, material planning, production, logistics, and supply chain management.
Microbot Medical (Nasdaq: MBOT) has elected David J. Wilson to its Board of Directors, strengthening its commercial capabilities as it prepares for the launch of the LIBERTY® Endovascular Robotic System. Wilson brings over 30 years of healthcare executive experience, including two decades at Johnson & Johnson where he served as Worldwide President of Cordis. He is currently CEO of InnovHeart and previously led Global Plasma at Haemonetics
The appointment aligns with Microbot's transition to a commercially focused organization, with the LIBERTY® system expected to launch in Q2 2025. Wilson replaces Yossi Bornstein, who served on the board since before the company went public in 2016. Wilson holds numerous medical device patents and has extensive experience in business strategy, R&D, and commercial product launches in the endovascular devices market.
Microbot Medical (Nasdaq: MBOT) has successfully closed its previously announced registered direct offering, raising $8.6 million in gross proceeds. The offering included 3,788,550 shares of common stock priced at $2.27 per share. Additionally, in a concurrent private placement, the company issued unregistered short-term series H preferred investment options to purchase up to 7,577,100 shares at $2.10 per share, exercisable immediately for two years.
The net proceeds will fund the continued development, commercialization, and regulatory activities for the LIBERTY® Robotic System, expand applications from existing IP portfolio, and provide working capital. H.C. Wainwright & Co. served as the exclusive placement agent for the offerings.
Microbot Medical (MBOT) has announced a registered direct offering priced at-the-market, selling 3,788,550 shares of common stock at $2.27 per share. The company will also issue unregistered short-term series H preferred investment options in a concurrent private placement, allowing the purchase of up to 7,577,100 shares at $2.10 per share, exercisable for two years.
The offerings, expected to close around January 9, 2025, will generate approximately $8.6 million in gross proceeds. H.C. Wainwright & Co. serves as the exclusive placement agent. The net proceeds will fund the development and commercialization of the LIBERTY® Robotic System, expand applications from existing IP portfolio, and provide working capital for general corporate purposes.
Microbot Medical (Nasdaq: MBOT) has successfully raised approximately $11.8 million in gross proceeds through multiple offerings. The company completed a registered direct offering of 4,000,001 shares at $1.75 per share, generating about $7 million. Additionally, they issued unregistered short-term series G preferred investment options for up to 8,000,002 shares with an exercise price of $1.75, exercisable for two years.
The company also raised approximately $4.8 million through their at-the-market facility through January 2025. H.C. Wainwright & Co. served as the exclusive placement agent. The proceeds will fund the development and commercialization of the LIBERTY® Robotic System, expand applications from their IP portfolio, and provide working capital for general corporate purposes.
Microbot Medical (Nasdaq: MBOT) has announced a $7 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 4,000,002 shares of common stock at $1.75 per share. Additionally, in a concurrent private placement, Microbot will issue unregistered short-term series G preferred investment options to purchase up to 8,000,004 shares of common stock at an exercise price of $1.75 per share, exercisable for two years.
The closing is expected around January 7, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent. The proceeds will fund the development and commercialization of the LIBERTY® Robotic System, expand applications from existing IP portfolio, and provide working capital for general corporate purposes.
Microbot Medical (Nasdaq: MBOT) has concluded 2024 with significant achievements, including the FDA 510(k) submission for its LIBERTY® Endovascular Robotic System. Key milestones include receiving IDE approval, completing the ACCESS-PVI pivotal human clinical trial across three major US medical centers, and obtaining ISO 13485 certification. The company has initiated inventory build-up and completed two phases of telesurgery collaboration with Corewell Health. Additionally, Microbot entered an agreement with Emory University for autonomous robotics development. The company anticipates launching LIBERTY in Q2 2025 in the U.S., with plans for international expansion.
Microbot Medical announces CEO Harel Gadot's upcoming interview on Benzinga All Access on December 10, 2024, at 10:50am ET. The discussion will focus on the company's LIBERTY® Endovascular Robotic System and the growing surgical robotics market.
The company has submitted an FDA 510(k) application for the LIBERTY® system, which is the world's first single-use, fully disposable endovascular robotic system. The technology eliminates the need for expensive capital equipment while offering benefits such as reduced radiation exposure for medical staff, improved ergonomics, potential cost savings, increased procedure efficiency, and enhanced quality of care.